Maxigesic (acetaminophen/ibuprofen) / AFT Pharma, Hyloris Pharma, BioSyent, Hikma - LARVOL DELTA

A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain (clinicaltrials.gov) - P3 | N=60 | Not yet recruiting | Sponsor: AFT Pharmaceuticals, Ltd.

New P3 trial • Pain • Pediatrics

A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery (clinicaltrials.gov) - P3 | N=180 | Not yet recruiting | Sponsor: AFT Pharmaceuticals, Ltd.

New P3 trial • Orthopedics • Pain

The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement (clinicaltrials.gov) - P=N/A | N=96 | Recruiting | Sponsor: Ajou University School of Medicine | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Aug 2024 ➔ Aug 2026

Enrollment open • Trial completion date • Trial primary completion date • Pain

IV meloxicam returns for treatment of pain. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Pain

Preemptive and Preventive Acetaminophen/Ibuprofen Fixed-dose Combination After Robot-assisted Radical Prostatectomy (clinicaltrials.gov) - P=N/A | N=154 | Completed | Sponsor: Seoul National University Hospital | Active, not recruiting ➔ Completed

Trial completion • Pain

Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients (clinicaltrials.gov) - P4 | N=25 | Terminated | Sponsor: Korea University Guro Hospital | N=176 ➔ 25 | Trial completion date: Dec 2025 ➔ Jan 2025 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2025 ➔ Jan 2025; The study was terminated early owing to challenges in completing the research registration process.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Geriatric Disorders • Lung Cancer • Oncology • Solid Tumor

Analgesic Efficacy of Maxigesic in Breast Cancer Surgery (clinicaltrials.gov) - P=N/A | N=84 | Recruiting | Sponsor: Yonsei University | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Feb 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Pain • Solid Tumor

Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section (clinicaltrials.gov) - P4 | N=84 | Recruiting | Sponsor: Seoul National University Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Enrollment open • Trial completion date • Trial primary completion date • Pain

Preemptive and Preventive Acetaminophen/Ibuprofen Fixed-dose Combination After Robot-assisted Radical Prostatectomy (clinicaltrials.gov) - P=N/A | N=154 | Active, not recruiting | Sponsor: Seoul National University Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Jul 2025 | Trial primary completion date: Aug 2024 ➔ Feb 2025

Enrollment closed • Trial completion date • Trial primary completion date • Pain

Drugs in Development to Manage Acute Pain. (PubMed, Drugs) - "These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain."

Journal • Review • Pain

A Pharmacokinetic study evaluating the pharmacokinetic parameters of different doses of Maxigesic® IV (intravenous paracetamol + intravenous ibuprofen) in healthy Japanese volunteers and Caucasian volunteers (ANZCTR) - P1 | N=24 | Completed | Sponsor: AFT Pharmaceuticals Ltd | Recruiting ➔ Completed

Trial completion

Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Seoul National University Hospital

New trial • Surgery • Breast Cancer • Oncology • Solid Tumor

Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section (clinicaltrials.gov) - P4 | N=84 | Not yet recruiting | Sponsor: Seoul National University Hospital

New P4 trial • Pain

A Pharmacokinetic study evaluating the pharmacokinetic parameters of different doses of Maxigesic® IV (intravenous paracetamol + intravenous ibuprofen) in healthy Japanese volunteers and Caucasian volunteers (ANZCTR) - P1 | N=24 | Recruiting | Sponsor: AFT Pharmaceuticals Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2024

Enrollment open • Trial initiation date

Intravenous acetaminophen/ibuprofen (Combogesic IV). (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Pain

Hikma announces US launch of COMBOGESIC IV (PRNewswire) - "Hikma Pharmaceuticals PLC...announces the launch of COMBOGESIC IV (acetaminophen and ibuprofen) injection in the US."

Launch US • CNS Disorders • Pain

A Pharmacokinetic study evaluating the pharmacokinetic parameters of different doses of Maxigesic® IV (intravenous paracetamol + intravenous ibuprofen) in healthy Japanese volunteers and Caucasian volunteers (ANZCTR) - P1 | N=24 | Not yet recruiting | Sponsor: AFT Pharmaceuticals Ltd

New P1 trial

Analgesic Efficacy of Maxigesic in Breast Cancer Surgery (clinicaltrials.gov) - P=N/A | N=84 | Recruiting | Sponsor: Yonsei University

New trial • Surgery • Breast Cancer • Oncology • Pain • Solid Tumor

Maxigesic_Lung: Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination on Postoperative Opioid Consumption (clinicaltrials.gov) - P=N/A | N=96 | Completed | Sponsor: Seoul National University Hospital | Recruiting ➔ Completed

Trial completion • Pain

Hyloris announces U.S. FDA Approval of Maxigesic IV (GlobeNewswire) - "Hyloris Pharmaceuticals SA...announces Maxigesic® IV has been approved for the relief of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics in adults, where an intravenous route of administration is considered clinically necessary. The approval for the New Drug Application (NDA) is based on positive data from a Phase 3 program..."

sNDA • CNS Disorders • Pain

Hyloris Pharma wins US FDA approval for pain treatment (Yahoo Finance) - "The U.S. health regulator has approved Hyloris Pharmaceuticals' drug for post-operative pain, the Belgium-based company said on Wednesday, adding that it expects to launch the non-opioid treatment in the United States by early next year. The injectable drug, branded as Maxigesic IV, was approved as a post-operative drug in hospitals or when patients cannot take medicine orally. The U.S. Food and Drug Administration's decision was based on data from a late-stage study that showed the drug to be more effective in relieving pain than commonly-used intravenous paracetamol."

NDA • CNS Disorders • Pain

Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients (clinicaltrials.gov) - P4 | N=176 | Recruiting | Sponsor: Korea University Guro Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Surgery • CNS Disorders • Geriatric Disorders • Lung Cancer • Oncology • Solid Tumor

The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement (clinicaltrials.gov) - P=N/A | N=96 | Not yet recruiting | Sponsor: Ajou University School of Medicine

New trial • Pain

Preemptive and Preventive Acetaminophen/Ibuprofen Fixed-dose Combination After Robot-assisted Radical Prostatectomy (clinicaltrials.gov) - P=N/A | N=154 | Recruiting | Sponsor: Seoul National University Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2023 ➔ Sep 2024 | Trial primary completion date: Sep 2023 ➔ Aug 2024

Enrollment open • Trial completion date • Trial primary completion date • Pain

Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination on Postoperative Opioid Consumption (clinicaltrials.gov) - P=N/A | N=96 | Recruiting | Sponsor: Seoul National University Hospital | Trial completion date: May 2024 ➔ Oct 2023

Surgery • Trial completion date • Pain